Tuesday, January 17, 2012

Goldman Keeps Merck At "Neutral", With Current NYSE-Quoted Prices Around $38


Given that Chairman/CEO Frazier gave a very thoughtful, and yet candid presentation last week, it must be more than a little disappointing that Goldman kept its non-favored stance on the Whitehouse Station company:

. . . .Goldman, Sachs & Co. reiterates "Neutral" rating on Merck. . .

So it goes.

No comments: